Opioid agonist/antagonist has a big impact in phase IIb trial ...

TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common ...

TuHURA (NASDAQ:HURA) addressed the American Society of Hematology (ASH) Annual Meeting and Exposition with a presentation and poster on Sunday, December 7 th in Orlando, Florida. Updated results from ...

Oral Presentation highlighted new scientific evidence that DOR is expressed on tumor-associated Myeloid-Derived Suppressor Cells (MDSCs), and its inhibition decreases immune suppressing capabilities ...

Anxiety-related disorders can have a profound impact on the mental health and quality of life of affected individuals. Understanding the neural circuits and molecular mechanisms that trigger anxiety ...

The global burden of anxiety- and depression-related disorders is on the rise. While multiple drugs have been developed to treat these conditions, current medications have several limitations, ...

Muse Treatment Alcohol & Drug Rehab Los Angeles has published a new educational resource that explains how opioid receptors ...

Oral presentation highlights the first time it's been demonstrated that the DOR is expressed on tumor-associated MDSCs, and that DOR inhibition reprograms multiple mechanisms of MDSC- induced ...